Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Regenerative Medicine Weekly Trend Line

Shares of regenerative medicine stem cell companies have been subject to continuous market gyrations.

At the end of the week (7/1/11), the NASDAQ was UP +42.51 (LW-33.86) (+1.53%) to 2816.03 (LW2652.89). The Dow was also UP 168.43 (LW+42.84) (+1.36) to 12,582.77 (LW: 11,934.58).

Glad to be back, we all have our own forms of withdrawal … mine is hearing from readers and their comments

Shares have been rebounding from lows of the past weeks.  Again, expect … LITTLE … during these summer months from the universe or economic maelstroms to “stem” overall risk sentiment.  (Last week close, 6/24/11 = LW)

 

Advancers (6):

  • Aastrom (ASTM) up +$0.01 (+0.36%) to $2.76 (LW $2.67);
  • BioTime (AMEX: BTX) up +$0.32 (+6.24%) to $5.45 (LW $4.75);  
  • Cytori (NASDAQ:CYTX) up +0.15 (+3.13%) to $4.94 (LW $4.85);  
  • Opexa (NASDAQ:OPXA) up +$0.05 (+3.14%) to $1.64 (LW $1.66);
  • Pluristem (NASDAQ:PSTI) up +0.08 (+2.76%) to $2.98 (LW $2.87);  and
  • ThermoGenesis (NASDAQ:KOOL) up +$0.02 (+1.0%) to $2.03 (LW $2.03).     

 

Decliners (11):   

  • Athersys (NASDAQ:ATHX) down -$0.01 (-0.37%) to  $2.70 (LW $2.74):  
  • BioMimetic (NASDAQ:BMTI) down -$0.42 (-8.20%) to $4.70 (LW $5.55);
  • Fibrocell Sciences (OTC: FCSC)  down -$0.005 (-0.58%) to $0.86 (LW:$0.95 );
  • Brainstorm (NASDAQ:BCLI) down -$0.022 (-4.47%) to $0.47 (LW $0.54);  
  • Geron (NASDAQ:GERN) down -0.02 (-0.50%) to $3.99 (LW $3.92);
  • ImmunoCellar Therapeutics (NYSEMKT:IMUC) down -$0.07 (-.3.18%) to $2.13 (LW $2.28);
  • International Stem Cell (ISCOE.OB) down -$0.04 (-3.70%) to $1.04 (LW $1.12);  
  • NeoStem (AMEX: NBS) down -$0.05 (-3.38%) to $1.43 (LW $1.72);
  • Osiris (NASDAQ:OSIR) down -$0.14 (-1.81%) to $7.60 (LW $7.60);
  • StemCells (STEM) down -$0.04 (-7.55%) to $0.49 (LW $0.54); and
  • Tengion (TNGN) down -$0.11 (-9.17%) to $1.09 (LW $1.35).

 

Flat (4):

  • Advanced Cell Technology (OTC: ACTC) flat at $0.1888 (LW $0.188);
  • BioHeart (OTCPK:BHRT) flat at $0.08 (LW:$0.08);  
  • Neuralstem (AMEX:CUR) flat at $1.50 (LW $1.66); and
  • ReNeuron Group (RENE.L) flat at $4.80 (LW $4.82).

               

The Bottom Line:  Declining stocks versus advancers (11 versus 6 compared to 8 versus 12 last week versus 9 and 9 from the previous week highlights visibility issues in indicators. This weeks biggest winners (that is a misnomer) of the regenerative medicine universe close were BioTime (AMEX: BTX) up +$0.32 (+6.24%) to $5.45; Cytori (CYTX) up +0.15 (+3.13%) to $4.94 followed by Pluristem (PSTI) up +0.08 (+2.76%) to $2.98.  So, how does it all lay out – regaining past highs! 

 

This Week’s Treatise: Visibility remains the major issue.  EU contagion is still exposure. Volume is volume but, buying the dips has been a fractured process. One comment resonates …IT IS HARD TO HOLD ON … TO A WINNER (appreciating stock) … in this market … for it is a defensive move …to SELL … and it is NEVER a problem to GET BACK in …

 

Retail trading dominates this market… investors seem to NEVER to take a full position through … questionable weekends … it is better to average up or down in this market

 

There is a NEW reality and expectation of “compromised” economic indicators but hopefully, the US economy … SHOULD … reaccelerate this FALL … I not sure I can wait!

 

The outlook for growth is … RegenMed/Stem cell stocks will continue to be volatile in this market … investors are “re-appreciation” the sector. It will be a highly lucrative sector; but the regulatory process is still the validation and the roadblock.

 

Going forward, in the short-term … I recognize 2 major shortcomings in RegMed investing – taking a long-term approach is fraught with trepidation in THIS MARKET … and looking for the best entry points seems to triggered a selloff … so for a while, investors … can’t POSITION a major stake in these small-cap shares without setting off a … PRICE run-up, and then … the (short position) SELLOFF … thus, investors can’t buy and sell shares without … SKEWING a stock’s pricing.

 

My bellwethers are still:  Athersys (ATHX), Cytori (CYTX), BioTime (AMEX: BTX), ImmunoCellular Therapeutics (NYSEMKT:IMUC), BioMimetic (BMTI) and Osiris (OSIR) …

 

I am STILL BULLISH on the future appreciation of NeoStem (AMEX: NBS) … even after a depreciation … having visited their Progenitor Cell Therapy (PCT) facility … NO one has YET factored in a sum-of-the-parts valuation … to and with … their evolving development scenario!